Key facts
- Notable investors include Antler.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Assyro AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Assyro AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Assyro AI
Developer of an AI-powered regulatory assistant designed to accelerate drug submissions, reduce compliance risk, and minimize costly rework for pharmaceutical and biotechnology companies. The company offers clause-level intelligence, real-time eCTD and RPS validation, and audit-ready tracking within a unified platform, enabling pharmaceutical and biotechnology companies to prepare, validate, and submit regulatory filings accurately, maintain inspection readiness, and shorten approval timelines for drugs, biologics, and medical devices.
- Sector
- Information Technology
- HQ
- Toronto, Canada
- Founded
- 2025
- Website
- assyro.com/
- Ownership
- Privately Held (backing)
Assyro AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Assyro AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Assyro AI in its N-PORT filings yet. We sweep new filings monthly.